Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Ysios Capital
by Miriam Cortes
1d ago
Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or rHTN is on track, with topline data expected for Advance-HTN trial in Q4 2024 and Launch-HTN trial in 2H 2025 – – Explore-CKD Phase 2 trial, a study for lorundrostat in hypertensive patients with stage 2-3b CKD on track for Q4 2024 to Q1 2025 topline data – – Conference call today at 8:30 a.m. ET – RADNOR, Pa., March 21, 2024 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease ..read more
Visit website
Lava provides business updates and reports fourth quarter and year-end financial results
Ysios Capital
by Miriam Cortes
1d ago
LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024 In March 2024, Pfizer paid LAVA $7 million for achieving a clinical milestone for EGFRd2 (PF-08046052/formerly LAVA-1223) LAVA 1266 tracking to Q2 2024 IND submission Strong balance sheet with cash of $95.6 million supports runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, March 20, 2024 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabod ..read more
Visit website
Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies
Ysios Capital
by Miriam Cortes
1w ago
Proceeds to Support Advancement of Engrail’s Pipeline for Neuropsychiatric and Neurodevelopmental Disorder SAN DIEGO – March 19, 2024 – Engrail Therapeutics (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced the close of an oversubscribed $157 million Series B financing round. The round was co-led by new investors F-Prime Capital, Forbion, and Norwest Venture Partners, with participation from RiverVest Venture Partners, Red Tree Venture Capital, funds managed by abrdn Inc., Ysio ..read more
Visit website
Fusion Pharmaceuticals To Be Acquired By AstraZeneca, Accelerating Development Of Next-Generation Radioconjugates To Treat Cancer
Ysios Capital
by Miriam Cortes
1w ago
Transaction includes actinium-based clinical-stage radioconjugate targeting PSMA for prostate cancer, pipeline of radioconjugates and state-of-the-art R&D and manufacturing facilities Fusion shareholders to receive $21.00 per share in cash at closing plus a non-transferrable contingent value right (CVR) of $3.00 per share, representing a total transaction value of approximately $2.4 billion including the CVR HAMILTON, ON and BOSTON, March 19, 2024 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company f ..read more
Visit website
NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)
Ysios Capital
by Miriam Cortes
1M ago
Phase 2a study evaluating the safety, tolerability, PK, and PD of Orziloben in IFALD The study will enroll up to 36 adult subjects at multiple sites in North America Study strengthens NST’s position as a multi-asset, clinical stage company AMSTERDAM–(BUSINESS WIRE)–NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other liver-associated metabolic diseases, today announced the dosing of the first patient in its Phase 2a clinical trial of Orziloben (NST-6179) in intestin ..read more
Visit website
Mineralys Therapeutics Announces $120 Million Private Placement Financing
Ysios Capital
by Miriam Cortes
1M ago
RADNOR, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (“CKD”) and other diseases driven by abnormally elevated aldosterone, today announced that it has entered into a securities purchase agreement with institutional accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $120 million, before deducting estimated fees and expenses. The financing was led by new investor TCGX ..read more
Visit website
Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders
Ysios Capital
by Miriam Cortes
1M ago
The financing, co-led by Viking Global Investors and Cormorant Asset Management with participation from The Column Group along with additional new and existing investors, follows promising early clinical data from NRTX-1001 epilepsy program San Francisco, CA, February 8, 2024 – Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the successful completion of a $120 million financing co-led by Viking Global Investors and Cormorant Asset Management with participati ..read more
Visit website
SparingVision Presents Initial SPVN06 Safety Data at the Macula Society 47th Annual Meeting
Ysios Capital
by Miriam Cortes
1M ago
No serious adverse events in the first two cohorts of patients dosed with SPVN06 (N=6) Observed ocular adverse events predominantly procedural, transient and resolved SparingVision founder, José-Alain Sahel, MD, awarded the Macula Society Michaelson Award Paris, 8 February 2024 – SparingVision (“the Company”), a clinical-stage genomic medicine company transforming the treatment of retinal disease, has presented positive initial safety data from the Phase I/II PRODYGY clinical trial of its lead gene-agnostic investigational gene therapy, SPVN06, for the treatment of retinitis pigmentosa (RP). D ..read more
Visit website
Inbiomotion and Source BioScience sign an exclusive agreement for MAF Test® in United Kingdom and Ireland
Ysios Capital
by Miriam Cortes
1M ago
This pioneering test aids oncologists in predicting recurrence and survival rates in breast cancer patients and potential treatment eligibility for bisphosphonates Results showing the clinical utility of the test have been published in Lancet Oncology and the Journal of National Cancer Institute The MAF Test® is now available to oncologists and pathologists in United Kingdom and Ireland and will benefit an estimated 56,000 new patients each year This agreement follows Inbiomotion’s recent distribution partnerships for Spain and Portugal with Palex Medical and The Scientific Group for Sub-Sahar ..read more
Visit website
Vivet Therapeutics receives EUR 4.9 million to advance development of a gene therapy
Ysios Capital
by Miriam Cortes
2M ago
Vivet Therapeutics receives EUR 4.9 million to advance development of a gene therapy for the treatment of cerebrotendinous xanthomatosis Funding from French Government as part of the France Health Innovation Plan 2030 operated by Bpifrance  Paris, France, February 1, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited metabolic disorders, announces the financing of EUR 4.9 million received from the French government to advance the development of a gene therapy for the treatment of cerebrotendinous x ..read more
Visit website

Follow Ysios Capital on FeedSpot

Continue with Google
Continue with Apple
OR